Safety and efficacy of REP 2139 and pegylated interferon alfa-2α for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial (vol 2, pg 877, 2017)

被引：0
|
作者：
Bazinet, M.
Pantea, V
Cebotarescu, V
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2018年 / 3卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E1 / E1
页数：1
相关论文
共 40 条
  • [31] SAFETY AND EFFICACY OF MK-5172 PLUS PEGINTERFERON ALFA-2b AND RIBAVIRIN (PR) IN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G)1 INFECTION
    Hezode, C.
    Bruno, S.
    Jacobson, I.
    Serfaty, L.
    Kwo, P.
    Zhou, A.
    Gilbert, C.
    Hwang, P.
    Wahl, J.
    Robertson, M. N.
    Mobashery, N.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S500 - S500
  • [32] Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial (vol 16, pg 685, 2016)
    Manns, M.
    Samuel, D.
    Gane, E. J.
    LANCET INFECTIOUS DISEASES, 2016, 16 (06): : 636 - 636
  • [33] Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection
    Wedemeyer, Heiner
    Schoeneweis, Katrin
    Bogomolov, Pavel O.
    Voronkova, Natalia
    Chulanov, Vladimir
    Stepanova, Tatyana
    Bremer, Birgit
    Allweiss, Lena
    Dandri, Maura
    Burhenne, Juergen
    Haefeli, Walter-Emil
    Ciesek, Sandra
    Dittmer, Ulf
    Alexandrov, Alexander
    Urban, Stephan
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E81 - E81
  • [34] Interim Results of a Multicentre, Open-Label Phase 2 Clinical Trial (MYR203) to Assess Safety and Efficacy of Myrcludex B in Combination with Peg-Interferon Alpha 2a in Patients with Chronic HBV/Hdv Co-Infection
    Wedemeyer, Heiner
    Schoeneweis, Katrin
    Bogomolov, Pavel O.
    Voronkova, Natalia V.
    Chulanov, Vladimir
    Stepanova, Tatyana
    Bremer, Birgit
    Lehmann, Patrick
    Raupach, Regina
    Alleiss, Lena
    Dandri, Maura
    Ciesek, Sandra
    Dittmer, Ulf
    Haefeli, Walter E.
    Alexandrov, Alexander
    Urban, Stephan
    HEPATOLOGY, 2018, 68 : 11A - 11A
  • [35] Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
    Bourliere, Marc
    Rabiega, Pascaline
    Ganne-Carrie, Nathalie
    Serfaty, Lawrence
    Marcellin, Patrick
    Barthe, Yoann
    Thabut, Dominique
    Guyader, Dominique
    Hezode, Christophe
    Picon, Magali
    Causse, Xavier
    Leroy, Vincent
    Bronowicki, Jean Pierre
    Carrieri, Patrizia
    Riachi, Ghassan
    Rosa, Isabelle
    Attali, Pierre
    Molina, Jean Michel
    Bacq, Yannick
    Tran, Albert
    Grange, Jean Didier
    Zoulim, Fabien
    Fontaine, Helene
    Alric, Laurent
    Bertucci, Inga
    Bouvier-Alias, Magali
    Carrat, Fabrice
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03): : 177 - 188
  • [36] Safety, tolerability, and anti-fibrotic efficacy of the CBP/I3-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study
    Kimura, Kiminori
    Kanto, Tatsuya
    Shimoda, Shinji
    Harada, Kenichi
    Kimura, Masamichi
    Nishikawa, Koji
    Imamura, Jun
    Ogawa, Eiichi
    Saio, Masanao
    Ikura, Yoshihiro
    Okusaka, Takuji
    Inoue, Kazuaki
    Ishikawa, Tetsuya
    Ieiri, Ichiro
    Kishimoto, Junji
    Todaka, Koji
    Kamisawa, Terumi
    EBIOMEDICINE, 2022, 80
  • [37] Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
    Lawitz, Eric
    Buti, Maria
    Vierling, John M.
    Almasio, Piero L.
    Bruno, Savino
    Ruane, Peter J.
    Hassanein, Tarek I.
    Muellhaupt, Beat
    Pearlman, Brian
    Jancoriene, Ligita
    Gao, Wei
    Huang, Hsueh-Cheng
    Shepherd, Aimee
    Tannenbaum, Brynne
    Fernsler, Doreen
    Li, Jerry J.
    Grandhi, Anjana
    Liu, Hong
    Su, Feng-Hsiu
    Wan, Shuyan
    Dutko, Frank J.
    Nguyen, Bach-Yen T.
    Wahl, Janice
    Robertson, Michael N.
    Barr, Eliav
    Yeh, Wendy W.
    Plank, Rebeca M.
    Butterton, Joan R.
    Yoshida, Eric M.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (11): : 814 - 823
  • [38] Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24weeks of treatment with Myrcludex B in combinationwith Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial
    Allweiss, L.
    Dettmer, C.
    Volz, T.
    Giersch, K.
    Alexandrov, A.
    Wedemeyer, H.
    Urban, S.
    Bockmann, J-H.
    Luetgehmann, M.
    Dandri, M.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S90 - S90
  • [39] Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial (vol 6, pg 448, 2021)
    Andrieux-Meyer, I
    Tan, S-S
    Thanprasertsuk, S.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (08): : 704 - 704
  • [40] Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
    Lawitz, Eric
    Gane, Edward
    Pearlman, Brian
    Tam, Edward
    Ghesquiere, Wayne
    Guyader, Dominique
    Alric, Laurent
    Bronowicki, Jean-Pierre
    Lester, Laura
    Sievert, William
    Ghalib, Reem
    Balart, Luis
    Sund, Fredrik
    Lagging, Martin
    Dutko, Frank
    Shaughnessy, Melissa
    Hwang, Peggy
    Howe, Anita Y. M.
    Wahl, Janice
    Robertson, Michael
    Barr, Eliav
    Haber, Barbara
    LANCET, 2015, 385 (9973): : 1075 - 1086
1234